First experiences with intraperitoneal chemotherapy in ovarian cancer.
The Authors report their experience with intraperitoneal chemotherapy in post surgical management of ovarian cancer. 24 patients were evaluable for the study and the results indicate that in patients with bulky disease the complication rate was high and the therapeutical outcome very poor. Only in patients with microscopic disease and residual tumor smaller than 2 cm seemed to benefit from intraperitoneal chemotherapy. Despite pharmacological advantages, Mitoxantrone causes local discomfort up to peritonitis.
Gitsch
E
E
1st Dept. Obstet. Gynec., Univ. Vienna.
Sevelda
P
P
Schmidl
S
S
Salzer
H
H
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use; D008942:Mitoxantrone / Q000008:administration & dosage / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010529:Peritoneal Cavity; D011379:Prognosis
D007370:Interferon Type I; D003561:Cytarabine; D008942:Mitoxantrone; D002945:Cisplatin